Guavus, a provider of big data analytics solutions, has acquired Neuralitic Systems, a mobile data monetization and marketing analytics experts serving the telecommunications industry. Guavus is backed by Investor Growth Capital, QuestMark Partners and previous investors Artiman Ventures, Sofinnova Ventures and Intel Capital.
You are browsing the archive for Sofinnova Ventures - peHUB.
Guavus, a provider of big data analytics solutions has closed a $30 million round of new funding. Investor Growth Capital led the round with participation from QuestMark Partners and previous investors Artiman Ventures, Sofinnova Ventures and Intel Capital.
Specialty pharmacy company Salveo Specialty Pharmacy has completed a second round of equity and debt funding and the subsequent acquisition of Mission Road Pharmacy. Salveo Specialty Pharmacy is backed by Three Arch Partners, NewSpring Capital and Petra Capital Partners. The additional equity financing was led by new investor Sofinnova Ventures. The debt financing included additional subordinated debt provided by Petra, as well as a new senior credit facility provided by Regions Bank.
Phizer is snapping up NextWave Pharmaceuticals—a company backed by a laundry list of investors including Panorama Capital, Bay City Capital, Kearny Venture Partners, Aisling Capital, Fidelity Biosciences, Sofinnova Ventures and Vivo Ventures. Under the terms of the deal, Pfizer will pay $255 million to NextWave’s shareholders at closing. NextWave’s shareholders are eligible to receive up to $425 million in additional money, based on sales milestones. NextWave closed a $45 million round last January.
Cebix Incorporated, a biopharmaceutical company developing treatments for complications of diabetes, has secured a $30.9M Series B investment. Prior investors InterWest, Sofinnova Ventures and Thomas, McNerney & Partners all participated in the financing. The company has also appointed Dr. Joel Martin as president and CEO.
Alimera Sciences, a biopharmaceutical company specialising in the research, development and commercialization of prescription ophthalmic pharmaceuticals, has secured a $40 million Series A financing. Palo Alto Investors acted as the lead investor in the offering, with Sofinnova Ventures and New Enterprise Associates also participating. PRESS RELEASE Alimera Sciences, Inc., (Nasdaq:ALIM) (Alimera), a biopharmaceutical company that [...]
UTIMCO Takes A Big Piece Of Ehrenberg’s New Fund, Adds Union Square, True Ventures And Artiman Funds: Slideshow
The University of Texas Management Company is among the largest investors in Roger Ehrenberg’s second fund, with a 30% stake of his new IA Ventures Strategies Fund II, according to a recent UTIMCO portfolio report.
Average investment multiples are higher for later stage and secondary commitments made since 2005, compared with other funds of the same vintages, and median IRRs for the later and secondary fund investments from earlier in the decade are better as well.
Catalyst Biosciences Inc. has sealed a $7 million milestone payment from Pfizer, as part of a research and license agreement between the two companies. Catalyst recently initiated Phase 1 clinical trials for one of its products, designed to help treat hemophilia patients. Privately held Catalyst is backed by investors including Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures and Sofinnova Ventures.